The spectrum of T cell metabolism in health and disease
In healthy individuals, metabolically quiescent T cells survey lymph nodes and peripheral
tissues in search of cognate antigens. During infection, T cells that encounter cognate …
tissues in search of cognate antigens. During infection, T cells that encounter cognate …
Interleukin‐6/STAT 3 signaling as a promising target to improve the efficacy of cancer immunotherapy
H Kitamura, Y Ohno, Y Toyoshima, J Ohtake… - Cancer …, 2017 - Wiley Online Library
Overcoming the immunosuppressive state in tumor microenvironments is a critical issue for
improving the efficacy of cancer immunotherapy. Interleukin (IL)‐6, a pleiotropic cytokine, is …
improving the efficacy of cancer immunotherapy. Interleukin (IL)‐6, a pleiotropic cytokine, is …
Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes
Y Elyahu, I Hekselman, I Eizenberg-Magar… - Science …, 2019 - science.org
Age-associated changes in CD4 T-cell functionality have been linked to chronic
inflammation and decreased immunity. However, a detailed characterization of CD4 T cell …
inflammation and decreased immunity. However, a detailed characterization of CD4 T cell …
Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
H Tsukamoto, K Fujieda, A Miyashita, S Fukushima… - Cancer research, 2018 - AACR
Recently emerging cancer immunotherapies combine the applications of therapeutics to
disrupt the immunosuppressive conditions in tumor-bearing hosts. In this study, we found …
disrupt the immunosuppressive conditions in tumor-bearing hosts. In this study, we found …
Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor–mediated natural killer cell function
A Stiff, P Trikha, B Mundy-Bosse, E McMichael… - Clinical Cancer …, 2018 - AACR
Purpose: mAbs are used to treat solid and hematologic malignancies and work in part
through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of …
through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of …
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
H Tsukamoto, Y Komohara, Y Tomita… - Proceedings of the …, 2022 - National Acad Sciences
Clinical success of immune-checkpoint blockade (ICB) cancer immunotherapy is
compromised by increased risk of immune-related adverse events (irAEs). However …
compromised by increased risk of immune-related adverse events (irAEs). However …
IL-10–producing Tfh cells accumulate with age and link inflammation with age-related immune suppression
M Almanan, J Raynor, I Ogunsulire, A Malyshkina… - Science …, 2020 - science.org
Aging results in profound immune dysfunction, resulting in the decline of vaccine
responsiveness previously attributed to irreversible defects in the immune system. In …
responsiveness previously attributed to irreversible defects in the immune system. In …
[HTML][HTML] Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
J Majidpoor, K Mortezaee - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Abstract Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High …
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High …
[HTML][HTML] Immune checkpoint inhibitors and elderly people: a review
A Daste, C Domblides, M Gross-Goupil… - European Journal of …, 2017 - Elsevier
Immune checkpoint inhibitors, including targeting programmed cell death 1, programmed
cell death ligand 1, and cytotoxic T lymphocyte antigen 4 pathways, are a new type of cancer …
cell death ligand 1, and cytotoxic T lymphocyte antigen 4 pathways, are a new type of cancer …
[HTML][HTML] High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
H Yang, B Kang, Y Ha, SH Lee, I Kim, H Kim, WS Lee… - JHEP Reports, 2023 - Elsevier
Background & Aims We elucidated the clinical and immunologic implications of serum IL-6
levels in patients with unresectable hepatocellular carcinoma (HCC) treated with …
levels in patients with unresectable hepatocellular carcinoma (HCC) treated with …